Ultragenyx Pharmaceutical AI Stock Analysis
Want to see RARE full AI Analyst Report?
Ultragenyx Pharmaceutical (RARE) AI Stock Analysis
Ultragenyx Pharmaceutical
(NASDAQ:RARE)
The score is held back primarily by weak financial performance (large losses, cash burn, and negative equity), while the latest earnings call provides meaningful offsets via major regulatory wins, nondilutive PRV cash proceeds, and a clearer 2027 profitability/cash-flow plan. Technicals are neutral and valuation is constrained by ongoing losses and no dividend.
Ultragenyx Pharmaceutical Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where Ultragenyx Pharmaceutical is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
North America remains the primary revenue engine but shows sharp quarter-to-quarter swings driven by seasonality and order timing; meanwhile Latin America, Europe and a nascent Japan business are growing fast—reflecting Crysvita and Evkeeza geographic rollouts and rising patient counts—which meaningfully diversifies the base. Management’s record-quarter claim is supported, but sustaining momentum and reaching the 2027 profitability plan still depends on continued commercial traction plus binary near‑term FDA outcomes (DTX‑401/UX‑111) and potential PRV monetization as backstop.
Ultragenyx Pharmaceutical (RARE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.62B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.60M
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 1.47
- Revenue Growth
- 15.76%
- EPS Growth
- 12.63%
- Country
- US
- Employees
- 1,371
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ultragenyx Pharmaceutical Business Overview & Revenue Model
Company Description
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international...
How the Company Makes Money
Ultragenyx makes money primarily by selling its commercial rare-disease medicines and recording product revenue from those sales. The company’s key revenue streams are: (1) Product sales of its approved therapies, where revenue is generated through d...
Ultragenyx Pharmaceutical Earnings Call Summary
The call had substantial positive developments, including two first-ever gene therapy approvals, strong demand and launch preparation, growth across established products, approximately $350 million in nondilutive proceeds, and reaffirmed 2027 profitability expectations. These were balanced by the GTX-102 Phase 3 failure, termination of UX701, a roughly 20% workforce reduction, restructuring charges, and uncertainty around the setrusumab regulatory path. Overall sentiment was mixed and balanced.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Ultragenyx reaffirmed 2026 total revenue guidance of $730 million to $760 million, excluding revenue from FAYUVI and GENGLYCOS, including CRYSVITA revenue of $500 million to $520 million and DOJOLVI revenue of $100 million to $110 million, and expects combined R&D and SG&A expenses to be flat to down low single digits versus 2025, including $30 million in severance and other nonrecurring restructuring charges from the first half of the year and approximately $25 million expected in the fourth quarter; for 2027, it expects to provide full year revenue guidance early in the new year, R&D expenses of less than $350 million, a reduction of more than 50% from 2025 levels, SG&A expenses of less than $375 million, an increase of up to 7% from 2025 levels, headcount reduced by approximately 20% to a revised workforce of approximately 1,000 employees, full year GAAP net income profitability and positive cash flow from operating activities, with net proceeds from the sale of two PRVs totaling approximately $350 million.
Ultragenyx Pharmaceutical Financial Statement Overview
Summary
Strong revenue momentum and high gross margins, but financial quality remains weak: deep ongoing losses, heavy operating/free-cash-flow burn, and negative equity that increases financing and dilution risk. Balance sheet uncertainty around debt levels further elevates risk despite improving commercial execution.
Income Statement
28NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 730.00M | 673.00M | 560.23M | 434.25M | 363.33M | 351.41M |
| Gross Profit | 605.00M | 564.00M | 483.50M | 389.04M | 335.01M | 335.40M |
| EBITDA | -417.21M | -474.00M | -469.00M | -516.45M | -640.49M | -410.32M |
| Net Income | -524.00M | -575.00M | -569.18M | -606.64M | -707.42M | -454.02M |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.53B | 1.50B | 1.49B | 1.55B | 1.52B |
| Cash, Cash Equivalents and Short-Term Investments | 266.00M | 693.00M | 610.02M | 577.21M | 747.76M | 740.20M |
| Total Debt | 1.19B | 1.28B | 40.34M | 43.17M | 31.59M | 41.97M |
| Total Liabilities | 1.56B | 1.60B | 1.24B | 1.22B | 1.19B | 599.84M |
| Stockholders Equity | -376.00M | -80.00M | 255.30M | 275.41M | 352.49M | 922.56M |
Cash Flow | ||||||
| Free Cash Flow | -441.77M | -472.00M | -421.68M | -521.57M | -526.59M | -411.79M |
| Operating Cash Flow | -436.83M | -466.00M | -414.19M | -474.81M | -380.46M | -338.69M |
| Investing Cash Flow | -19.25M | 236.00M | -17.77M | 168.00M | -291.65M | -195.37M |
| Financing Cash Flow | 407.19M | 478.00M | 399.24M | 388.14M | 501.21M | 118.55M |
Ultragenyx Pharmaceutical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RARE, the sentiment is Negative. The current price of 15.90 is below the 20-day moving average (MA) of 16.25, above the 50-day MA of 15.30, and below the 200-day MA of 22.49, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 37.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RARE.
Ultragenyx Pharmaceutical Risk Analysis
Ultragenyx Pharmaceutical disclosed 61 risk factors in its most recent earnings report. Ultragenyx Pharmaceutical reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksUltragenyx Pharmaceutical Peers Comparison
Overall Rating
IRON68Neutral
TARS54Neutral
RARE53Neutral
TVTX48Neutral
XENE46Neutral
MLYS42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | $3.49B | -12.21 | -36.33% | ― | ― | -18.27% | |
| 54Neutral | $3.88B | -5.14 | -245.72% | ― | 86.34% | -654.07% | |
| 53Neutral | $1.62B | -3.08 | 213.22% | ― | 15.76% | 12.63% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $4.77B | -32.00 | -186.46% | ― | 49.38% | -58.47% | |
| 46Neutral | $3.86B | -8.35 | -39.80% | ― | -100.00% | -21.09% | |
| 42Neutral | $1.29B | -3.38 | -63.26% | ― | ― | -47.55% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical, Inc. | 15.90 | -16.93 | -51.57% | |
| TVTX | Travere Therapeutics, Inc. | 49.70 | 13.70 | 38.06% | |
| XENE | Xenon Pharmaceuticals | 39.26 | -1.35 | -3.32% | |
| IRON | Disc Medicine, Inc. | 76.59 | -13.15 | -14.65% | |
| TARS | Tarsus Pharmaceuticals, Inc. | 78.68 | 1.71 | 2.22% | |
| MLYS | Mineralys Therapeutics, Inc. | 14.53 | -28.86 | -66.51% |
Ultragenyx Pharmaceutical Corporate Events
Ultragenyx Announces Workforce Reduction and Strategic Restructuring
NegativeOn October 30, 2026, Ultragenyx completed the sale of its GENGLYCOS-related Rare Pediatric Disease Priority Review Voucher for $210 million. The FDA had awarded the voucher on August 19 after approving GENGLYCOS for patients aged eight and older with...
Ultragenyx, Baylor Reach Settlement on DOJOLVI Patents
NeutralOn October 19, 2026, Ultragenyx Pharmaceutical Inc. and Baylor Research Institute reached a settlement with Navinta LLC, resolving patent litigation over patents covering Ultragenyx’s DOJOLVI triheptanoin oral liquid. The dispute stemmed from Navinta...
Ultragenyx Sells FDA Priority Review Voucher for Cash
PositiveOn October 8, 2026, Ultragenyx Pharmaceutical Inc. agreed to sell a Rare Pediatric Disease Priority Review Voucher that it had received from the U.S. Food and Drug Administration on September 17, 2026, following approval of FAYUVI (UX111) for treatin...
Ultragenyx Monetizes FDA Priority Review Voucher Asset
PositiveOn October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher that it received from the U.S. Food and Drug Administration on August 19, 2026, following approval of...
Ultragenyx wins FDA approval for FAYUVI gene therapy
PositiveOn September 17, 2026, Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration granted full approval to FAYUVI, also known as UX111, for treating pediatric patients with mucopolysaccharidosis type IIIA, or Sanfilippo syndr...
Ultragenyx pivots strategy after Aspire Phase 3 setback
NegativeOn September 2, 2026, Ultragenyx reported Phase 3 results from the Aspire study of apazunersen (GTX-102) in Angelman syndrome, showing the trial failed to meet its primary cognitive endpoint and key secondary multidomain responder endpoint. With no e...
Ultragenyx Wins FDA Accelerated Approval for GENGLYCOS
PositiveOn August 19, 2026, Ultragenyx announced that the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients eight years and older with glycog...
Ultragenyx Settles DOJOLVI Patent Dispute with Esjay
PositiveOn August 7, 2026, Ultragenyx Pharmaceutical and Baylor Research Institute reached a settlement with Esjay Pharma resolving U.S. patent litigation over DOJOLVI, after Esjay filed an Abbreviated New Drug Application to market a generic version. Under...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
